 HBV, hepatitis B virus; HCV, hepatitis C virus; HCVcc, hepatitis C virus in cell culture; HCV-LP, HCV-like particle; HCVpp, hepatitis C virus pseudoparticles; IFN, interferon; mAbs, monoclonal antibodies; MLV, murine leukemia virus; NAbs, neutralizing 
Introduction
The hepatitis C virus (HCV) is a major pathogen known to cause chronic liver disease, which may progress to cirrhosis and hepatocellular carcinoma. This virus is thus a leading cause of liver transplantation in industrialized countries. 1 Chronic HCV infection is currently a major public health problem, affecting approximately 3% of the world population. 2, 3 Moreover, it has been estimated that more than 350,000 people die from HCV-related liver disease each year, worldwide. 4 Over the last 10 years, it has been shown that progression to severe disease can be prevented by treatment with a combination of pegylated interferon (IFN)- and ribavirin.
However, the efficacy of this treatment is limited, with a sustained virological response rate of only 55%, and this treatment is poorly tolerated, often impairing quality of life. 5, 6 Given these disappointing results, researchers have focused their efforts in recent years on characterizing the multiple steps of the HCV life cycle, with a view to identifying new treatment targets for the development of novel antiviral molecules. The standard treatment has, in some cases (particularly in patients infected with HCV genotype 1), recently been supplemented with the newly approved NS3/4A protease inhibitors, better known as telaprevir and boceprevir. 7 This triple therapy increases sustained response rates, but its use is nonetheless limited by its very high cost, potential drug-drug interactions and substantial side effects.
Despite these considerable therapeutic advances, it is estimated that world reservoir of HCV-infected individuals is increased by three to four million newly infected subjects each year. This increase is not limited to developing countries, as the Center for Disease Control and Prevention (CDC) has estimated that 18,000 new HCV infections occur each year in the USA, corresponding to about one new case every 30 minutes. 8 The development of safe, effective and affordable prophylactic vaccines against HCV has thus become a major medical widely accepted that for a vaccine formulation to provide effective protection against the various genotypes and quasispecies of HCV, it must incorporate epitopes from HCV structural proteins (core, E1, E2) in their correct three-dimensional conformations, to induce the production of high titers of broad NAbs, together with HCV-specific T-cell epitopes from HCV nonstructural proteins (NS3, NS4, NS5), to elicit strong cellular responses. 26 The recent development of an efficient system for HCV culture 27 
Early vaccination strategies based on the recombinant HCV envelope glycoproteins E1 and E2
Most of the successful prophylactic vaccines against viruses developed to date are effective mostly through the action of NAbs. A prophylactic vaccination strategy based on the use of adjuvanted recombinant E1 and E2 viral envelope proteins was, therefore, initially proposed.
This prophylactic vaccine effectively protected immunized chimpanzees against experimental intravenous challenge with the homologous 1a strain. 32, 33 Moreover, additional studies in chimpanzees demonstrated that this prophylactic vaccine did not result in sterilizing immunity against experimental challenge with a heterologous 1a strain, instead inhibiting disease progression to chronic, persistent infection. 33 As human disease is almost exclusively associated with chronic, persistent HCV infection rather than with acute infection, these data indicated that a prophylactic vaccine based on the E1-E2 viral envelope proteins might be effective at protecting against HCV-associated disease in humans. cell culture (HCVcc) containing E1 and E2 envelope proteins derived from various genotypes. 34 These data indicate that this recombinant E1/E2 vaccine can elicit crossneutralizing antibodies targeting broadly conserved epitopes within the diverse Hepacivirus genus, with no apparent cellular immune response. Based on these encouraging data, a doseranging phase I trial was initiated to explore the safety and immunogenicity of this recombinant E1-E2 vaccine, which was found to be well tolerated and immunogenic in humans volunteers. 28, 35, 36 Many other studies have since demonstrated that the resolution of HCV infection is mediated largely by the effects of NAbs raised against the HCV E1 and E2 envelope proteins, which are exposed on the surface of viral particles. 
38-41
These data are all very encouraging, but there is a major obstacle hindering the further development of this vaccine candidate. The coexpression of the full-length E1 and E2 genes has been shown to result in the synthesis of highly mannosylated immature glycoforms with a transmembrane domain (TMD) anchoring them in intracellular compartments in the form of a large, noncovalently linked heterodimer, making the extraction and purification of these proteins extremely difficult and essentially incompatible with industrial development for vaccination purposes. 42, 43 These difficulties have led to the development of alternative strategies based on the use of truncated E1 and/or E2 proteins, which are then secreted.
However, such approaches have met with limited success, because the deletion of the TMD of inserm-00812949, version 1 -13 Apr 2013
these proteins has been shown to impair their antigenic and functional properties.
44,45

Promising innovative virus-like particle (VLP)-based vaccination strategies
In the last few years, new vaccination approaches involving the use of VLP-based vaccines have thus been developed to improve the delivery system for HCV neutralizing antibody-and core-specific T-cell epitopes. This approach is justified by previous reports of convincing demonstrations of the efficacy of VLP-based vaccines, particularly for preventing persistent infection and associated diseases caused by hepatitis B virus (HBV) 46 and human papillomavirus. 47 The generation of HCV-like particles (HCV-LPs) in insect cells has been described and involves the use of a recombinant baculovirus containing the complementary DNA (cDNA) encoding the HCV structural proteins. 48 These HCV-LPs have been shown to have morphological, biophysical and antigenic properties similar to those of the putative virions, 49 and to be highly immunoreactive when incubated with purified antibodies from the serum of patients infected with various HCV genotypes or with various mAbs recognizing conformational determinants, suggesting that they contain correctly assembled HCV structural proteins. 49 antibodies, and of NAbs, in both mice and macaques. 60 The NAbs, which were raised against genotype 1a HCV, cross-neutralized the five other genotypes tested (1b, 2a, 2b, 4 and 5) in vitro. The results of all these studies were encouraging, supporting the development of retrovirus-derived VLP-based vaccines, but the multiple-dose regimen required to induce a protective immune response nonetheless represents a major difficulty. Moreover, the use of animal retroviral particles for the development of a prophylactic vaccine for humans will require validation, and the large-scale vaccine manufacturing process may represent a bottleneck for the development of vaccines of this type. An alternative approach, overcoming the difficult production of such retrovirus-derived VLPs, involves the direct injection of DNA plasmids encoding proteins generating retrovirus-derived VLPs (plasma-retroVLPs) into mice. 61 This new genetic vaccination approach has been shown to elicit similar HCV-specific immune responses.
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The . 46 The use of these particles as carriers of small foreign viral antigenic sequences inserted into the antigenic external hydrophilic loop [64] [65] [66] 70 or the N-or Cterminus 71, 72 of HBV S has also since been reported. However, the capacity of these chimeric proteins to self-assemble into VLPs and the induction of an effective immune response were not systematically demonstrated. In efforts to develop an original strategy for incorporating the entire HCV E1 and E2 proteins into these particles, a new concept in vaccine design was recently developed, based on the use of plasmids encoding chimeric HBV-HCV envelope proteins in which the N-terminal TMD of S is replaced with the TMD of E1 or E2. 67 When produced in stably transduced Chinese hamster ovary (CHO) cells, these chimeric HBV-HCV envelope proteins were efficiently coassembled with the wild-type S protein into subviral secreted particles presenting the full-length E1 and E2 proteins in an appropriate inserm-00812949, version 1 -13 Apr 2013
conformation for formation of the E1-E2 heterodimer. 68 These chimeric particles induced a strong specific antibody response to the HCV and HBV envelope proteins in immunized rabbits. More importantly, rabbit sera containing anti-E1 and/or anti-E2 antibodies elicited by this vaccination strategy had cross-neutralizing properties in vitro against HCVpp and HCVcc harboring heterologous HCV envelope proteins derived from strains of genotypes 1a, 1b, 2a and 3, highlighting the importance of including both envelope proteins for an effective vaccination strategy. 68 Moreover, the humoral anti-HBs response induced by these particles was shown to be equivalent to that observed in animals immunized with a commercial HBV vaccine. Further studies are required to increase the broadly neutralizing properties of the NAbs induced by this vaccination strategy, and to investigate this specific HCV-neutralizing response in different animal models, but the encouraging data generated by this study support the development of a bivalent HBV-HCV prophylactic vaccine candidate potentially able to prevent initial infection with either of these two hepatotropic viruses. Such a vaccine would be of considerable value, because the populations at risk of infection with HBV and HCV through exposure to infected blood are essentially the same, in both developed and developing countries. 73 In this context, the induction by HBV-HCV envelope particles of an anti-HBs response equivalent to that induced by commercially available HBV vaccines is also important, as it suggests that bivalent HBV-HCV vaccines could replace existing vaccines against HBV whilst providing the additional benefit of protection against HCV. Another major advantage of this approach is that this vaccine candidate could be produced by the same 
